Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | IGF1R | P08069 | 7/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.54 |
| ▸ | AURKA | O14965 | 8/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230471 | 1.00 | ITK (0.65) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL2120764 | 0.84 | ITK (0.62) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL29537888 | 0.84 | ITK (0.62) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL18154778 | 0.81 | ITK (0.59) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL18297005 | 0.80 | ITK (0.58) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL802275 | 0.79 | ITK (1.00) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL13675364 | 0.79 | ITK (0.56) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL18154760 | 0.79 | ITK (0.56) | ITKKDRIGF1RFGFR1AURKA | |
| SCHEMBL12060073 | 0.79 | NEK1 (0.64) | IGF1RSRCPAK4 | |
| SCHEMBL30353181 | 0.78 | ITK (0.55) | ITKKDRIGF1RFGFR1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3283482-A1 | PLK4 INHIBITORS | Ludwig Institute for Cancer Research Ltd (CH) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016166604-A1 | PLK4 INHIBITORS | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | ITK 1823/4885KDR 1853/4885IGF1R 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.